



ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to the ShareSoc Members Network (<http://sharesoc.ning.com>) in a Forum entitled "ShareSoc Growth Company Seminar Reports" soon after the Seminar. Use the site search facility at top right to locate those for a particular company if you cannot find the Forum.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Evgen Pharma

EVG  18.25p ▲ 0.8 4.3%Highly Speculative, Micro Cap, Momentum Trap

Market Cap

£18.1m

Quality

14

Enterprise Value

£14.4m

Value

3

Revenue

£n/a

Momentum

66

Market Cap Rank

1489th / 1920

StockRank™**17**Zoom 1m 3m 6m YTD **1y** 2y 3y 5y All**Momentum**

Relative Strength (%)

1m +19.9% ●

3m +11.2% ●

1yr +22.7% ●

Volume Change (%)

10d v 3m +52.2% ●

Price vs... (%)

52w High -37.6% ●

50d MA +13.3% ●

200d MA +10.8% ●

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (f) n/a

PEG Ratio (f) n/a

EPS Growth (f) n/a %

Dividend Yield (f) n/a %

Valuation (ttm)

Price to Book Value 4.66

Price to Tang. Book 4.80

Price to Free Cashflow n/a

Price to Sales n/a

EV to EBITDA n/a

Quality

vs. industry vs. market

Return on Capital -78.2 %

Return on Equity -63.8 %

Operating Margin n/a %

Health Trend Piotroski F-Score

3

**Bankruptcy Risk** Altman Z2-Score

42.9

**Earnings Manipulation Risk**

N/A

Magic Formula Score

2722 7% E-

**Other Ratios**

Leverage (ttm)	total	-intang	+pension
Gross Gearing	%		
Net Gearing	%	-93.7	-93.7
Cash / Assets	%	85.1	85.1

Liquidity (ttm)	Efficiency (ttm)
Curr. Ratio	10.6 ● Asset Turnover n/a
Quick Ratio	10.6 ● Rec's Turnover n/a
Interest Cov.	n/a Stock Turnover n/a

Recent History

vs. industry vs. market

Latest interim period (ended 31st Mar '18) vs. prior year

Sales Growth n/a % **EPS Growth** n/a %

3yr Compound Annual Growth Rate

Sales Growth n/a % **EPS Growth** n/a % **DPS Growth** n/a % **Margin of Safety (beta)**

Broker Target	519%
Relative to Sector	-26%
Stability Value (EPV)	80%


Screens Passed

EVG doesn't qualify for any screens.
Find out why: [View Checklists](#)


Financial Summary

Balance Sheet · Income Statement · Cashflow

Year End 31st Mar		2013	2014	2015	2016	2017	2018	2019E	2020E	CAGR / Avg
Revenue	£m	0.000	0.000	0.000	0.000	0.000	0.000	3.75	3.75	
Operating Profit	£m	-0.95	-0.96	-1.25	-2.43	-3.66	-3.03			
Net Profit	£m	-0.87	-1.08	-2.27	-3.13	-3.07	-2.58	-3.09	-3.45	
EPS Reported	p	-1.19	-1.48	-3.12	-6.29	-4.19	-3.28			
EPS Normalised	p	-1.19	-1.48	-2.86	-5.40	-4.19	-3.28	-3.30	0.29	
EPS Growth	%									
PE Ratio	x						n/a	n/a	64.0	
PEG	x						n/a	n/a	n/a	
Profitability										
Operating Margin	%									
ROA	%		-245.9	-493.1	-80.8	-50.5				
ROCE	%	-538.1	-254.5		-34.3	-86.5	-78.2			-165.3%
ROE	%		-603.4		-106.2	-54.2	-63.8			-165.5%
Cashflow										
Op. Cashflow ps	p	-1.07	-1.09	-1.24	-3.13	-4.36	-2.97			
Capex ps	p	0.047	0.000	0.001	0.084	0.10	0.009			-28.2%
Free Cashflow ps	p	-1.11	-1.09	-1.24	-3.22	-4.47	-2.98			
Dividends										
Dividend ps	p									
Dividend Growth	%									
Dividend Yield	%									
Dividend Cover	x									
Balance Sheet										
Cash etc	£m	0.11	0.31	0.16	7.13	3.86	3.63			+100.1%
Working Capital	£m	0.12	0.32	-0.17	7.01	4.09	3.75			+100.4%
Net Fixed Assets	£m	0.002	0.001	0.001	0.006	0.011	0.012			+43.1%
Net Debt	£m	-0.11	-0.16	0.90	-7.13	-3.86	-3.63			
Book Value	£m	0.18	0.18	-1.19	7.09	4.23	3.87			+85.6%
Average Shares	m	72.9	72.9	72.9	49.8	73.2	78.7			+1.6%
Book Value ps	p	0.24	0.25	-1.63	9.69	5.77	4.15			+76.6%

Graphical History Current Fiscal Year 2019

Broker Forecasts				31st Mar 2019			31st Mar 2020		
Price Target: 1.13 (+519.21% above Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				-3.09m	-3.30	-	-3.45m	0.29	-
1m Change				-	-	-	-	-	-
3m Change				-	-	-	-	+3.99	-



Profile Summary

evgen pharma

Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.

Directors: [Barry Clare](#) (CHM) 62, [Stephen Franklin](#) (CEO) 47, [Richard Moulson](#) (CFO), [Hamina Patel](#) (OTH), [Alan Barge](#) (NED) 58, [Susan Clement-Davies](#) (NED), [Sue Foden](#) (NED) 62,

No. of Employees: 2

No. of Shareholders: n/a

Last Annual	March 31st, 2018	Sector	Healthcare
Last Interim	March 31st, 2018	Industry	Biotechnology & Medical Research
Incorporated	October 2, 2014	Index	FTSE Aim All Share ,
Public Since	October 21, 2015	Exchange	London Stock Exchange (AIM)
Shares in Issue	98,912,416	Eligible for	an ISA? a SIPP?
Free Float	79.8m (80.7%)		



Address [The Colony,146 Brownlow Hill](#)
[Altrincham Road, WILMSLOW, SK9 4LY,](#)
[United Kingdom](#)

Web <http://evgen.com/>

Phone +44 151 7053532

Contact ()

Auditors RSM UK Audit LLP

EVGQuote				EVG Share Price Performance			
EVG Share Price GBP	Day's Change	Volume	Bid - Ask	Low - High	Spread		
18.25p	▲ 0.8 4.3%	171,095	17.5 - 19.0	0.0 - 0.0	822bps		
Traded 3:35pm · Minimum 15 min delayed · NMS: 3.00k		Avg Vol (3m)	Open - Close	12m Range	Beta		
		96,344	17.5 - 18.3	12.8 - 27.6	0.00		

Latest EVG News Announcements <i>(delayed)</i>		More »
8th Nov	Evgen Pharma PLC - Directorate Changes	
23rd Oct	Evgen Pharma PLC - Holding(s) in Company	
18th Oct	BRIEF-Evgen Pharma Raises £0.75 Mln Via Placing Of 5.6 Mln New Shares	
18th Oct	Evgen Pharma PLC - Placing	
18th Sep	Evgen Pharma PLC - Investor Symposium	

Upcoming EVG Events
Recent ↓

Industry Peer Group	
Motif Bio	☐
Compare vs EVG	
4D Pharma	☐
Compare vs EVG	
Mainstay Medical I...	☐
Compare vs EVG	
Verona Pharma	☐
Compare vs EVG	
Verseon	☐
Compare vs EVG	
Bioventix	☐
Compare vs EVG	
Oxford Biodynamics	☐
Compare vs EVG	
Circassia Pharmace...	☐
Compare vs EVG	

[Healthcare](#) [Biotechnology & Medical Research](#)

Ideagen

IDEA 140p ▲ 1.0 0.7%

Adventurous, Small Cap, **High Flyer**

Market Cap

£306.9m

Quality

94

Enterprise Value

£306.1m

Value

3

Revenue

£36.1m

Momentum

▼ 76

Market Cap Rank

714th / 1920

StockRank™

61

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum

Relative Strength (%)

1m -10.7% ●

3m +12.2% ●

1yr +67.1% ●

Volume Change (%)

10d v 3m -2.44% ●

Price vs... (%)

52w High -20.0% ●

50d MA -8.06% ●

200d MA +7.19% ●

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (f) 26.4

PEG Ratio (f) 0.62

EPS Growth (f) 73.3 %

Dividend Yield (f) 0.21 %

Valuation (ttm)

Price to Book Value 6.08

Price to Tang. Book n/a

Price to Free Cashflow 50.5

Price to Sales 8.50

EV to EBITDA 35.6

Margin of Safety (beta)



Screens Passed 2

IDEA qualifies for **Price Momentum Screen (in Momentum Investing)**.[View Screen](#) · [View Checklist](#)

Quality

vs. industry vs. market

Return on Capital 2.58 %

Return on Equity 3.16 %

Operating Margin 3.98 %

Financial Summary


Balance Sheet · Income Statement · Cashflow

Year End 30th Apr		2013	2014	2015	2016	2017	2018	2019E	2020E	CAGR / Avg
Revenue	£m	6.51	8.97	14.4	21.9	27.1	36.1	46.5	54.3	+40.9%
Operating Profit	£m	-1.45	1.06	0.79	1.00	0.70	1.44			
Net Profit	£m	-0.81	0.87	0.48	1.32	0.73	1.53	9.90	10.9	
EPS Reported	p	-0.87	0.68	0.34	0.71	0.38	0.74			
EPS Normalised	p	0.65	0.84	0.58	0.71	0.62	0.92	4.80	5.70	+7.2%
EPS Growth	%	+172.7	+29.1	-30.3	+21.2	-12.7	+48.4	+423.4	+18.8	
PE Ratio	x						152.7	29.2	24.6	
PEG	x						0.36	1.56	n/a	
Profitability										
Operating Margin	%	-22.3	11.8	5.5	4.6	2.6	4.0			+1.0%
ROA	%		4.8	1.4	2.7	1.2	2.0			
ROCE	%	-11.1	7.2	2.1	2.6	1.3	2.6			+0.8%
ROE	%		6.8	2.2	4.1	1.8	3.2			+3.6%
Cashflow										
Op. Cashflow ps	p	1.76	0.96	1.23	2.56	4.34	4.27			+19.3%
Capex ps	p	0.51	0.46	0.73	1.07	1.19	1.33			+21.1%
Free Cashflow ps	p	1.25	0.50	0.50	1.50	3.16	2.94			+18.6%
Dividends										
Last ex-div: 1st Nov, paid: 21st Nov more...										
Dividend ps	p		0.15	0.17	0.18	0.21	0.24	0.30	0.30	
Dividend Growth	%			+10.00	+10.9	+14.8	+14.8	+24.5		
Dividend Yield	%						0.17	0.21	0.21	
Dividend Cover	x		4.54	2.04	3.86	1.81	3.06	16.0	19.0	
Balance Sheet										
Cash etc	£m	6.37	4.01	5.27	6.32	6.21	5.53			-2.8%
Working Capital	£m	4.95	2.60	1.23	3.85	-5.21	-5.27			
Net Fixed Assets	£m	0.41	0.34	1.18	1.31	1.93	0.79			+14.2%
Net Debt	£m	-6.37	-4.01	-5.27	-6.32	-4.21	-0.78			
Book Value	£m	12.3	13.4	31.2	33.7	46.4	50.5			+32.7%
Average Shares	m	92.1	128.3	143.1	186.3	191.8	207.1			+17.6%
Book Value ps	p	10.1	11.0	17.6	18.8	23.4	24.9			+19.8%

Health Trend

Piotroski F-Score

9



Bankruptcy Risk

Altman Z2-Score

11.5



Earnings Manipulation Risk

Low

Magic Formula Score

969 63% B-



Other Ratios

Leverage (ttm)		total	-intang	+pension
Gross Gearing	%	9.41		9.41
Net Gearing	%	-1.55		-1.55
Cash / Assets	%	6.99		6.99
Liquidity (ttm)		Efficiency (ttm)		
Curr. Ratio	0.77	●	Asset Turnover	0.48
Quick Ratio	0.77	●	Rec's Turnover	3.36
Interest Cov.	95.9	●	Stock Turnover	633.2

Recent History

vs. industry vs. market

Latest interim period (ended 30th Apr '18) vs. prior year

Sales Growth 25.6 %

EPS Growth -6.04 %


3yr Compound Annual Growth Rate

Sales Growth 35.9 %


EPS Growth 16.2 %

DPS Growth 13.5 %

Graphical History Current Fiscal Year 2019



Broker Forecasts				30th Apr 2019			30th Apr 2020		
Price Target: 1.80 (+28.61% above Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				9.90m	4.80	0.30	10.9m	5.70	0.30
1m Change				-	-	-	-	-	-
3m Change				-	-	-	-	+0.50	-



Profile Summary



Ideagen plc is engaged in the development and sale of information management software to businesses in various industries, and the provision of associated professional services and support. The Company is engaged in supplying governance, risk and compliance (GRC) solutions primarily to the healthcare, transport, aerospace and defense, manufacturing and financial services sectors. The Company's portfolio products include Q-Pulse, Coruson, Pentana Audit, Pentana Performance and PleaseReview. Q-Pulse, which provides quality and safety management. Coruson, which provides cloud-based software solution. Pentana is an auditing software within its internal audit. It has operations in the United Kingdom, European Union, the United States, Middle East and Southeast Asia.

Directors: [David Hornsby](#) (CEO), [Graeme Spenceley](#) (FID), [Barnaby Kent](#) (COO) 40, [Jonathan Wearing](#) (NEC), [Alan Carroll](#) (NED), [Tony Rodriguez](#) (NED) 48,

No. of Employees: 423

No. of Shareholders: n/a

Last Annual April 30th, 2018
Last Interim April 30th, 2018

Incorporated March 30, 1993

Shares in Issue 219,224,013
Free Float 176.7m (80.6%)

Sector [Technology](#)
Industry [Software & IT Services](#)
Index [FTSE Aim All Share](#), [FTSE Aim 100](#),
Exchange [London Stock Exchange \(AIM\)](#)
Eligible for an ISA? [✓](#) a SIPP? [✓](#)

Address [Lime Tree Business Park Lime Tree Road, RUDDINGTON, NG11 6JS, United Kingdom](#)
Web <https://www.ideagen.com/>
Phone +44 1629 699100
Contact [Paul Cornelius](#) (IR Contact Officer)
Auditors RSM UK Audit LLP

IDEAQuote

IDEA Share Price
GBP

Day's Change

▲ 1.0 0.7%

140p

Traded 4:36pm · Minimum 15 min delayed · NMS: 5.00k

Volume
5,070,496

Avg Vol (3m)
661,740

Bid - Ask
140.0 - 142.0

Open - Close
139.0 - 140.0


Low - High
140.0 - 140.0

12m Range
108.0 - 172.5

Spread
143bps

Beta
0.05

IDEA Share Price Performance



Latest IDEA News Announcements (delayed)

[More »](#)

- Tue 8:44am [BRIEF-Ideagen Says HY Trading Has Remained Strong](#)
- Tue 7:00am [Ideagen PLC - Trading Update](#)
- 30th Oct [Ideagen PLC - Result of AGM](#)
- 24th Oct [Ideagen PLC - Exercise of Options and Total Voting Rights](#)
- 23rd Oct [Ideagen PLC - Holding\(s\) in Company](#)

Upcoming IDEA Events

Recent ↓

Industry Peer Group

- [TruFin](#)
[Compare vs IDEA](#)
- [LoopUp](#)
[Compare vs IDEA](#)
- [dotDigital](#)
[Compare vs IDEA](#)
- [Microgen](#)
[Compare vs IDEA](#)
- [Codemasters Group](#)
[Compare vs IDEA](#)
- [Frontier Developme...](#)
[Compare vs IDEA](#)
- [accesso Technology](#)
[Compare vs IDEA](#)
- [GB](#)
[Compare vs IDEA](#)

[Technology](#)

[Software & IT Services](#)